LOGIN TO YOUR ACCOUNT

Username
Password
Remember Me
Or use your Academic/Social account:

CREATE AN ACCOUNT

Or use your Academic/Social account:

Congratulations!

You have just completed your registration at OpenAire.

Before you can login to the site, you will need to activate your account. An e-mail will be sent to you with the proper instructions.

Important!

Please note that this site is currently undergoing Beta testing.
Any new content you create is not guaranteed to be present to the final version of the site upon release.

Thank you for your patience,
OpenAire Dev Team.

Close This Message

CREATE AN ACCOUNT

Name:
Username:
Password:
Verify Password:
E-mail:
Verify E-mail:
*All Fields Are Required.
Please Verify You Are Human:
fbtwitterlinkedinvimeoflicker grey 14rssslideshare1
Hu, Wenbing; Luo, Qun; Wu, Kui; Li, Xianchan; Wang, Fuyi; Chen, Yi; Ma, Xiaoyan; Wang, Jianping; Liu, Jianan; Xiong, Shaoxiang; Sadler, Peter J. (2011)
Publisher: ROYAL SOC CHEMISTRY
Journal: CHEMICAL COMMUNICATIONS
Languages: English
Types: Article
Subjects: RC0254, QD, QP
Cisplatin, cis-[Pt(Cl2(NH3)2], can crosslink residues His67 of domain I and His247 of domain II in human albumin, occupying the major binding site for the essential metal zinc on the protein.
  • The results below are discovered through our pilot algorithms. Let us know how we are doing!

    • Nos: 90713020, 20975103 and 21020102039), the Chinese
    • Academy of Sciences (Hundred Talent Program), the 973
    • 30 (Grant No: 2007CB935601), European Research Council (Grant
    • no. 247450) and ERDF/AWM /Science City for support, and Drs.
    • Warwick and members of EC COST Action D39 for stimulating
    • Chem istry, Chinese Academ y of Sciences, Beijing 100190, PR China. Fax:
    • 40 (+86) 10-6252-9069; E-mail:
    • Coventry CV4 7AL, UK. Fax: (+44) 24-765 23818; E-mail:
    • 45 details of HPLC and ESI-MS/MS analysis, tryptic digestion and
    • molecular modeling; Table S1 and Figure S1-S7. See
    • DOI: 10.1039/b000000x/
    • 1 (a) D. Wang, S. J. Lippard, Nat. Rev. Drug Discovery, 2005, 4, 307;
    • (b) R. F. Ozols, Cancer Treat. Rev., 1991, 18, 77; (c) M. A. Jakupec,
    • Trans., 2008, 183; (d) B. Lippert, Cisplatin. Chemistry and
    • 1999. 2 (a) L. Kelland, Nat. Rev. Cancer, 2007, 7, 573; (b) M. S. Davies, S. J.
    • Berners-Price, T. W. Hambley, Inorg. Chem., 2000, 39, 5603. 3 (a) Y. W. Jung, S. J. Lippard, Chem. Rev., 2007, 107, 1387; (b) S. T .
    • 2002, 124, 1558; (c) Y. Zou, B. Van Houten, N. Farrell, Biochem istry,
    • 1994, 33, 5404; (d) H. Baruah, C. G. Barry, U. Bierbach, Curr. Top.
    • Med. Chem ., 2004, 4, 1537. 4 (a) A. R. Timerbaev, C. G. Hartinger, S. S. Aleksenko, B. K. Keppler,
    • Chem . Rev., 2006, 106, 2224; (b) C. Gabbiani, F. Magherini, A.
    • Modesti, L. Messori, Anti-Cancer Agents Med. Chem., 2010, 10, 324;
    • Chem ., 2008, 47, 17; (d) D. Gibson, Dalton Trans., 2009, 10681. 5 (a) R. C. Todd, S. J. Lippard, Metallomics, 2009, 1, 280; (b) A.
    • Eastman, Canc. Cell. Mon. Rev., 1990, 2, 275. 6 (a) R. C. Deconti, B. R. Toftness, R. C. Lange, W. A. Creasey,
    • Cancer Res., 1973, 33, 1310; (b) I. Khalaila, A. Bergamo, F. Bussy,
    • G. Sava, P. J. Dyson, Int. J. Oncol., 2006, 29, 261; (c) D. Esteban-
    • A. Palacios, A. Sanz-Medel, J. Anal. At. Spectrom., 2008, 23, 378; (d)
    • Woolley, Cancer Chemother. Pharmacol., 1980, 5, 21. 7 M. Sooriyaarachchi, A. Narendran, J. Gailer, Metallom ics, 2011, 3,
    • 49. 8 D. C. Carter, J. X. Ho, Adv. Protein Chem ., 1994, 45, 153. 9 (a) C. A. Blindauer, I. Harvey, K. E. Bunyan, A. J. Stewart, D. Sleep,
    • D. J. Harrison, S. Berezenko, P. J. Sadler, J. Biol. Chem., 2009, 284,
    • 23116; (b) J. Lu, A. J. Stewart, P. J. Sadler, T. J. T. Pinheiro, C. A.
    • Blindauer, Biochem. Soc. Trans., 2008, 36, 1317; (c) A. J. Stewart, C.
    • Sci. U. S. A., 2003, 100, 3701. 10 A. I. Ivanov, J. Christodoulou, J. A. Parkinson, K. J. Barnham, A.
    • T ucker, J. Woodrow, P. J. Sadler, J. Biol. Chem., 1998, 273, 14721. 11 J. Will, D. A. Wolters, W. S. Sheldrick, ChemMedChem , 2008, 3,
    • 1696. 12 J. D. Sweeney, P. Ziegler, C. Pruet, M. B. Spaulding, Cancer, 1989,
    • 63, 2093. 13 The binding of cisplatin to Cys124 is particularly remarkable because
    • this residue forms a disulfide with Cys169 in rHA itself. Although
    • Pharm ., 1992, 85, 39. 14 The zinc indicator 4-(2-pyridylazo)resorcinol (PAR) was used to
    • experimental section in SI). 15 T. J. Peters, All About Album in: Biochemistry, Genetics, and Medical
    • Applications., Academic Press, 1995. 16 (a) A. Gerl, R. Schierl, Acta Oncol., 2000, 39, 519; (b) E. Moreno-
    • 2010, 135, 1288. 17 R. P. Sharma, Pharmacol. Res. Commun., 1985, 17, 197. 18 (a) D. Hagrman, J. Goodisman, J. C. Dabrowiak, A. K. Souid, Drug
    • Metab. Disposition, 2003, 31, 916; (b) M. Knipp, A. V. Karotki, S.
    • 2007, 50, 4075; (c) G. X. Zhang, W. B. Hu, Z. F. Du, S. Lv, W.
    • Mass Spectrom., 2011, DOI: 10.1016/j.ijms.2010.12.003. 19 Q. A. de Paula, J. B. Mangrum, N. P. Farrell, J. Inorg. Biochem.,
    • 2009, 103, 1347. 20 (a) L. Maurmann, R. N. Bose, Dalton Trans, 2010, 39, 7968-7979; (b)
    • Biophys., 1993, 13, 135. 21 S. Curry, H. Mandelkow, P. Brick, N. Franks, Nat. Struct. Biol., 1998,
  • No related research data.
  • No similar publications.
  • BioEntity Site Name
    1bm0Protein Data Bank

Share - Bookmark

Published in

Funded by projects

  • EC | BIOINCMED

Cite this article